<DOC>
	<DOCNO>NCT00244179</DOCNO>
	<brief_summary>1. investigate , whether one two alternative therapy strategy ( antibiotic plus immunostimulation versus antibiotic plus immunosuppression ) chronic reactive arthritis therapeutical superior conventionel standardtherapy ( DMARD ) . 2. investigate , whether one different therapy strategy cause altered detection bacterial DNA joint colon . 3. measure antigen-specific -unspecific immune response ( predominantly t-cell response ) therapy correlate clinical course . 4. gain knowledge analyse clinical course concern pathogenesis point attack possible therapy chronic reactive arthritis . 5. compare cytokine-profiles CD4- CD8-positive T-cells patient treat infliximab treat etanercept .</brief_summary>
	<brief_title>New Immunomodulatory Therapy Strategies Chronic Reactive Arthritis</brief_title>
	<detailed_description>Studybackground Enteric reactive arthritis ( ReA ) extraintestinal manifestation infection colon mucosa cause enterobacteria . At least chronic course ReA bacterial persistence assume likely locate colon mucosa colon associate lymph node . The persistence bacteria might consequence insufficient t-helper-immune-response . On hand persistence pathogen could harmless local immune-pathology could cause hypersensitivity immune response The project hand shall assess whether 1 . ) immune stimulation immune suppression best therapy chronic reactive arthritis 2 . ) enteric reactive arthritis base bacterial persistence hypersensitivity immune response . By gain data hope able draw conclusion concern pathogenesis therapy infection affect mucosa . ReA occur infection intestine ( enteric ReA ) urogenital infection cause chlamydia ( urogenital ReA ) . Both form ReA pathogenetically und immunogenically closely relate treat one entity . Patients enrol trial enteric ReA ( colon possible location bacterial persistence ) , urogenital ReA ( location bacterial persistence know ) undergo colonoscopy treatment-period obtain colon biopsy work . Patients knee involvement ( arthritis knee ) undergo arthroscopy treatment-period obtain synovial biopsy work . Recently collect data form group concern patient ankylose spondylitis therapy infliximab etanercept show potential CD4- CD8-positive t-cells produce interferon gamma ( IFN Gamma ) tumornecrosisfactor alpha ( TNF-Alpha ) antigen-specific –unspecific stimulation distinct reduce therapy infliximab , whereas potential therapy etanercept increase . In context recently collect data concern Crohn´s disease assume bind soluble TNF-Alpha well membrane-associated TNF-Alpha infliximab induces apoptosis t-cells , whereas etanercept induces apoptosis . These result could explain , infliximab etanercept effective treat Crohn´s disease Furthermore induction apoptosis could explain therapy infliximab associate high incidence tuberculosis compare etanercept . By mean FACS ( Fluorescence activate cell sort ) want examine , whether TNF-blocking agent patient chronic ReA induce t-cell-suppression compare cytokine-pattern CD4- CD8-positive t-cells patient treat infliximab cytokine-pattern CD4- CD8-positive t-cells patient treat etanercept . The comparison therapies - infliximab etanercept – special interest , TNF-blocking agent obviously different active profile well different side effect . Background dosage Ciprofloxacin 2 x 500 mg p.o . daily conventional therapy treat infection enterobacteria . Clinical trial infliximab 5 mg/kg patient suffer ankylose spondylitis successfully perform . Dosages infliximab 1 – 10 mg/kg use treat succesfully patient rheumatoid arthritis . A dosage 5 mg/kg effective 1 mg/kg , 10 mg/kg slightly well . Infliximab approve indication rheumatoid arthritis ankylose spondylitis . Clinical trial etanercept 25 mg s.c. 2 x per week patient suffer ankylose spondylitis rheumatoid arthritis perform successfully effectively . Etanercept approve indication ankylose spondylitis , rheumatoid arthritis psoriasic-arthritis . To treat patient suffer tuberculosis respond conventional anti-tuberculosis-therapy IFN-g ( interferon-gamma ) 3 x 100 – 150 µg/week s.c. succesfully administer . In clinical trial ass efficacy rheumatoid arthritis IFN-g 50 µg administer daily first three week every day last week . Patients receive standard-therapy ( Sulphasalazine , Methotrexate , Leflunomide ) treat common dosage drug deduce common treatment rheumatoid arthritis . Background selection patient 80 % patient suffer acute ReA heal within 6 month . About 40 % patient severe symptom 6 month 20 % develop chronic course arthritis . These patient chronic ReA regrettably insufficiently treat available drug ( NSAID , Methotrexate , Sulphasalazine , Leflunomide ) . Patients enrol trial definite chronic ReA ( disease duration least 12 month ) , joint pain &gt; 4 ( visual analogue scale , 0-10 ) , constant demand NSAID active arthritis affect least one joint .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Reactive</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1. definite classification arthritis ReA enteric ReA define arthritis , occur within 4 week precede symptomatic infection gut enteric bacteria yersinia , salmonella , campylobacter jejuni , shigella . If symptomatic precede infection remember trigger enterobacterium clearly identify serology stool culture . Other cause diarrhea like example inflammatory bowel disease eliminate . urogenital ( chlamydiatriggered ) ReA define arthritis , occur within 4 week symptomatic urogenital infection infection upper airways chlamydia clearly identify serology direct proof . 2. disease duration &gt; 12 month 3. age 18 70 year 4. active arthritis least one joint 5. constant demand NSAIDs 6. intensity pain &gt; 4 visual analogue scale ( VAS ; 0 10 ) 7. patient allow treat socalled conventional therapy ( Sulphasalazine , Methotrexate etc . ) steroid i.a . , stop 4 week enrol trial 8. able selfadminister s.c. injection caregiver 9. woman child bear potential must negative pregnancy test study baseline use adequate , effective method contraception ( implant , injectables , combine oral contraceptive , IUDs , sexual abstinence , vasectomised partner ) duration 6 month stop therapy . Sexual active men must use accepted method contraception duration 6 month stop therapy . 10. read normal chest/ lung xray , negative MendelMantouxskin test ( 10,0 TE ) ( old 4 week ) . If MendelMantouxskin test positive / hint heal tuberculosis chest xray ( latent tuberculosis ) patient shall receive infliximab etanercept additional therapy isoniazid 300 mg daily start 4 week first administration infliximab etanercept give . 11. sign inform consent 1. female subject pregnant breastfeed 2. previous treatment cytokine anticytokines ( biological agent ) 3. severe infection within last 3 month 4. history opportunistic infection within last 2 month ( herpes zoster , cytomegaly virus , pneumocystis cariniiinfection ) 5 . HIVinfection 6. history malignancy 7. receipt live ( attenuate ) vaccine within last 30 day screen visit 8. previous diagnosis sign demyelinate disease 9. history uncontrolled diabetes , unstable ischemic heart disease , active inflammatory bowel disease , active peptic ulcer disease , recent stroke , ongoing congestive heart failure , condition , opinion investigator , would put subject risk participation protocol . 10. history cytopenia 11. laboratory exclusion : hemoglobin level &lt; 8,5 g/dl , white blood cell count &lt; 3.5 x109/l , platelet count &lt; 125 x 109 /l , creatinine level &gt; 175 µmol/ liver enzymes &gt; 1,5 , alkaline phosphatase &gt; 2 time upper limit normal , Quick &gt; 50 . 12. clinical examination show significant abnormality clinical relevance 13. participation trial investigational medication within 30 day enter study 14. history current evidence abuse ” hard ” drug ( e.g . cocaine/heroine ) 15. current medication 7,5 mg Prednisolon daily</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>reactive arthritis</keyword>
	<keyword>trial</keyword>
	<keyword>interferon-gamma</keyword>
	<keyword>infliximab</keyword>
	<keyword>chronic</keyword>
	<keyword>tnf-blocker</keyword>
</DOC>